Efficacy of Combined Paclitaxel and Oxaliplatin Therapy in Patients with Pretreated Advanced Non Small Cell Lung Cancer
XIE Cong Ying, WU Shi Xiu, ZHANG Ping Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou,Zhejiang,325000, P.R.China
BACKGROUND OBJECTIVE: No chemotherapeutic regimen and agent are effective for patients with pretreated advanced non small cell lung cancer (NSCLC). This study was designed to evaluate the efficacy and toxicity of the combination of paclitaxel and oxaliplatin in this subset of patients. METHODS: Twenty two patients who had been pretreated with platinum based chemotherapy were enrolled into this study. All received paclitaxel (135 mg/m2, intravenous infusion over 3 hours on day 1) and oxaliplatin (130 mg/m2, intravenous infusion over 2 hours on day 1) every 28 days. The whole course of treatment consisted at least 2 cycles. RESULTS: Of 22 patients, 5 achieved partial response with the overall response rate of 22.7%. Nearly all lesions shrank or remained stable after the first 2 cycles, except for those of 3 patients who showed progressive diseases. Median progression free duration time was 4 months, and median survival time was 8 months. Commonly encountered toxicities included nausea and vomiting, myalgia/arthralgta, peripheral neuropathy, and myelosuppression. CONCLUSION: Paclitaxel plus oxaliplatin combination was a safe and active regimen for patients with pretreated advanced NSCLC and deserves further evaluation.
【CateGory Index】： R734.2